Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seidman, A.
Right arrow Articles by Keefe, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seidman, A.
Right arrow Articles by Keefe, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 5 (March), 2002: 1215-1221
© 2002 American Society for Clinical Oncology

Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

By Andrew Seidman, Clifford Hudis, Mary Kathryn Pierri, Steven Shak, Virginia Paton, Mark Ashby, Maureen Murphy, Stanford J. Stewart, Deborah Keefe

From the Memorial Sloan-Kettering Cancer Center, New York, NY; and Genentech Inc, South San Francisco, CA.

Address reprint requests to Andrew Seidman, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: seidmana{at}mskcc.org

PURPOSE: This study sought to estimate cardiac dysfunction (CD) risk for patients receiving trastuzumab; to characterize observed CD by severity, treatment, and clinical outcome; to assess effects of baseline clinical risk factors on CD; and to assess effects of cumulative doses of anthracyclines and trastuzumab on CD.

PATIENTS AND METHODS: A retrospective review of records for patients enrolled onto any of seven phase II and III trastuzumab clinical trials was performed. Predefined criteria were used for the diagnosis, and the New York Heart Association functional classification system was used to document CD severity. Product-limit estimates were used to summarize the cumulative anthracycline and trastuzumab doses at the time of CD onset.

RESULTS: Patients treated with trastuzumab were found to be at an increased risk for CD. The incidence was greatest in patients receiving concomitant trastuzumab and anthracycline plus cyclophosphamide (27%). The risk was substantially lower in patients receiving paclitaxel and trastuzumab (13%) or trastuzumab alone (3% to 7%); however, most of these patients had received prior anthracycline therapy. CD was noted in 8% of patients receiving anthracycline plus cyclophosphamide and 1% receiving paclitaxel alone. Most trastuzumab-treated patients developing CD were symptomatic (75%), and most improved with standard treatment for congestive heart failure (79%).

CONCLUSION: Trastuzumab is associated with an increased risk of CD, which is greatest in patients receiving concurrent anthracyclines. In most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzumab.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
F. G. VAN ROOIJ, L. D.A. DORRESTEIJN, M. M.J.A. VAN BOKHOVEN, and C. C.P. VERSTAPPEN
A Throbbing Pain in the Head: Trastuzumab-induced Migraine
Anticancer Res, October 1, 2009; 29(10): 4223 - 4225.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Di Lorenzo, R. Autorino, G. Bruni, G. Carteni, E. Ricevuto, M. Tudini, C. Ficorella, C. Romano, M. Aieta, A. Giordano, et al.
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
Ann. Onc., September 1, 2009; 20(9): 1535 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. T.H. Yeh and C. L. Bickford
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al.
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Clin. Cancer Res., April 15, 2009; 15(8): 2895 - 2904.
[Abstract] [Full Text] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
R. L. Barros Costa
Review Article: Targeted Therapy: Comprehensive Review
American Journal of Hospice and Palliative Medicine, April 1, 2009; 26(2): 137 - 146.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-K. Wong, P. M. Fracasso, R. M. Bukowski, T. J. Lynch, P. N. Munster, G. I. Shapiro, P. A. Janne, J. P. Eder, M. J. Naughton, M. J. Ellis, et al.
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Clin. Cancer Res., April 1, 2009; 15(7): 2552 - 2558.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
K. Y. Wonders and B. S. Reigle
Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise
Integr Cancer Ther, March 1, 2009; 8(1): 17 - 21.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Cortes, S. Di Cosimo, M. A. Climent, H. Cortes-Funes, A. Lluch, P. Gascon, J. I. Mayordomo, M. Gil, M. Benavides, L. Cirera, et al.
Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
Clin. Cancer Res., January 1, 2009; 15(1): 307 - 314.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
P. G. Morris, H. L. McArthur, C. T. Dang, and C. A. Hudis
Selection of Appropriate Patients for Anthracycline Therapy
ASCO Educational Book, January 1, 2009; 2009(1): 11 - 18.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Oncologist, January 1, 2009; 14(1): 1 - 11.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. J. Lenihan and F. J. Esteva
Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer
Oncologist, December 1, 2008; 13(12): 1224 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies
Ann. Onc., September 1, 2008; 19(9): 1530 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. Gomez, D. C. Doval, M. A. Chavez, P. C.-S. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W.C. Chow, M. C. Arbushites, et al.
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
J. Clin. Oncol., June 20, 2008; 26(18): 2999 - 3005.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Burstein, A. M. Storniolo, S. Franco, J. Forster, S. Stein, S. Rubin, V. M. Salazar, and K. L. Blackwell
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
Ann. Onc., June 1, 2008; 19(6): 1068 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Belkacemi, J. Gligorov, M. Ozsahin, H. Marsiglia, B. De Lafontan, H. Laharie-Mineur, L. Aimard, E.-C. Antoine, B. Cutuli, M. Namer, et al.
Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study
Ann. Onc., June 1, 2008; 19(6): 1110 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
E. A. Perez, M. Koehler, J. Byrne, A. J. Preston, E. Rappold, and M. S. Ewer
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Mayo Clin. Proc., June 1, 2008; 83(6): 679 - 686.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
B. L. Frei and S. A. Soefje
A Review of the Cardiovascular Effects of Oncology Agents
Journal of Pharmacy Practice, April 1, 2008; 21(2): 146 - 158.
[Abstract] [PDF]

Home page
 JCOHome page
E. A. Perez, V. J. Suman, N. E. Davidson, G. W. Sledge, P. A. Kaufman, C. A. Hudis, S. Martino, J. R. Gralow, S. R. Dakhil, J. N. Ingle, et al.
Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
J. Clin. Oncol., March 10, 2008; 26(8): 1231 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
P. P. Sengupta, D. W. Northfelt, F. Gentile, J. L. Zamorano, and B. K. Khandheria
Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads
Mayo Clin. Proc., February 1, 2008; 83(2): 197 - 203.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
A. Ramond, E. Sartorius, M. Mousseau, C. Ribuot, and M. Joyeux-Faure
Erythropoietin Pretreatment Protects Against Acute Chemotherapy Toxicity in Isolated Rat Hearts
Experimental Biology and Medicine, January 1, 2008; 233(1): 76 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. R.J. H. Bird and S. M. Swain
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Oncologist, December 1, 2007; 12(12): 1443 - 1455.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu
Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling
Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R. Kumar, T. P. Quinn, and S. L. Deutscher
Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor Expressing Breast Carcinomas
Clin. Cancer Res., October 15, 2007; 13(20): 6070 - 6079.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Lemmens, K. Doggen, and G. W. De Keulenaer
Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure
Circulation, August 21, 2007; 116(8): 954 - 960.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S.-A. Pearson, C. L. Ringland, and R. L. Ward
Trastuzumab and Metastatic Breast Cancer: Trastuzumab Use in Australia Monitoring the Effect of an Expensive Medicine Access Program
J. Clin. Oncol., August 20, 2007; 25(24): 3688 - 3693.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Telli, S. A. Hunt, R. W. Carlson, and A. E. Guardino
Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
J. Clin. Oncol., August 10, 2007; 25(23): 3525 - 3533.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Beauclair, P Formento, J. Fischel, W Lescaut, R Largillier, E Chamorey, P Hofman, J. Ferrero, G Pages, and G Milano
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
Ann. Onc., August 1, 2007; 18(8): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. R. Correa, H. I. Litt, W.-T. Hwang, V. A. Ferrari, L. J. Solin, and E. E. Harris
Coronary Artery Findings After Left-Sided Compared With Right-Sided Radiation Treatment for Early-Stage Breast Cancer
J. Clin. Oncol., July 20, 2007; 25(21): 3031 - 3037.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. A. Hudis
Trastuzumab -- Mechanism of Action and Use in Clinical Practice
N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51.
[Full Text] [PDF]

Home page
 NEJMHome page
H. L. McArthur and S. Chia
Cardiotoxicity of Trastuzumab in Clinical Practice
N. Engl. J. Med., July 5, 2007; 357(1): 94 - 95.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist, March 1, 2007; 12(3): 253 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Gabrielson, D. Bedja, S. Pin, A. Tsao, L. Gama, B. Yuan, and N. Muratore
Heat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury
Cancer Res., February 15, 2007; 67(4): 1436 - 1441.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. N. Harris, F. You, S. J. Schnitt, A. Witkiewicz, X. Lu, D. Sgroi, P. D. Ryan, S. E. Come, H. J. Burstein, B.-A. Lesnikoski, et al.
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1198 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. N. Munster, C. D. Britten, M. Mita, K. Gelmon, S. E. Minton, S. Moulder, D. J. Slamon, F. Guo, S. P. Letrent, L. Denis, et al.
First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors
Clin. Cancer Res., February 15, 2007; 13(4): 1238 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
A. Glazyrin, X. Shen, V. Blanc, and J. F. Eliason
Direct Detection of Herceptin/Trastuzumab Binding on Breast Tissue Sections
J. Histochem. Cytochem., January 1, 2007; 55(1): 25 - 33.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Moy and P. E. Goss
Lapatinib: Current Status and Future Directions in Breast Cancer
Oncologist, November 1, 2006; 11(10): 1047 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Guarneri, D. J. Lenihan, V. Valero, J.-B. Durand, K. Broglio, K. R. Hess, L. B. Michaud, A. M. Gonzalez-Angulo, G. N. Hortobagyi, and F. J. Esteva
Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience
J. Clin. Oncol., September 1, 2006; 24(25): 4107 - 4115.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. M. Gonzalez-Angulo, G. N. Hortobagyi, and F. J. Esteva
Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer
Oncologist, September 1, 2006; 11(8): 857 - 867.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. L. Garland, M. Hidalgo, D. S. Mendelson, D. P. Ryan, B. K. Arun, J. L. Lovalvo, I. A. Eiseman, S. C. Olson, P. F. Lenehan, and J. P. Eder
A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors.
Clin. Cancer Res., July 15, 2006; 12(14): 4274 - 4282.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Robert, B. Leyland-Jones, L. Asmar, R. Belt, D. Ilegbodu, D. Loesch, R. Raju, E. Valentine, R. Sayre, M. Cobleigh, et al.
Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer
J. Clin. Oncol., June 20, 2006; 24(18): 2786 - 2792.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Chia, M. Clemons, L.-A. Martin, A. Rodgers, K. Gelmon, G. R. Pond, and L. Panasci
Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial
J. Clin. Oncol., June 20, 2006; 24(18): 2773 - 2778.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Piekarz, A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo, and S. E. Bates
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma.
Clin. Cancer Res., June 15, 2006; 12(12): 3762 - 3773.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. G. Horan, M. F. McMullin, and P. P. McKeown
Anthracycline cardiotoxicity
Eur. Heart J., May 2, 2006; 27(10): 1137 - 1138.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al.
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
Ann. Onc., April 1, 2006; 17(4): 630 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. P. Coudert, L. Arnould, L. Moreau, P. Chollet, B. Weber, L. Vanlemmens, C. Molucon, N. Tubiana, S. Causeret, J.-L. Misset, et al.
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
Ann. Onc., March 1, 2006; 17(3): 409 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Neyt, J. Albrecht, and V. Cocquyt
An economic evaluation of Herceptin(R) in adjuvant setting: the Breast Cancer International Research Group 006 trial
Ann. Onc., March 1, 2006; 17(3): 381 - 390.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Tan-Chiu, G. Yothers, E. Romond, C. E. Geyer Jr, M. Ewer, D. Keefe, R. P. Shannon, S. M. Swain, A. Brown, L. Fehrenbacher, et al.
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31
J. Clin. Oncol., November 1, 2005; 23(31): 7811 - 7819.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Ewer, M. T. Vooletich, J.-B. Durand, M. L. Woods, J. R. Davis, V. Valero, and D. J. Lenihan
Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment
J. Clin. Oncol., November 1, 2005; 23(31): 7820 - 7826.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Floyd, D. T. Nguyen, R. L. Lobins, Q. Bashir, D. C. Doll, and M. C. Perry
Cardiotoxicity of Cancer Therapy
J. Clin. Oncol., October 20, 2005; 23(30): 7685 - 7696.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. H. Romond, E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer Jr., N. E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman, et al.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
N. Engl. J. Med., October 20, 2005; 353(16): 1673 - 1684.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Campos, O. Hamid, M. V. Seiden, A. Oza, M. Plante, R. K. Potkul, P. F. Lenehan, E. P. Kaldjian, M. L. Varterasian, C. Jordan, et al.
Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer
J. Clin. Oncol., August 20, 2005; 23(24): 5597 - 5604.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. A. Burris III, H. I. Hurwitz, E. C. Dees, A. Dowlati, K. L. Blackwell, B. O'Neil, P. K. Marcom, M. J. Ellis, B. Overmoyer, S. F. Jones, et al.
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
J. Clin. Oncol., August 10, 2005; 23(23): 5305 - 5313.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Ewer and S. M. Lippman
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
J. Clin. Oncol., May 1, 2005; 23(13): 2900 - 2902.
[Full Text] [PDF]

Home page
 JCOHome page
S. K. Mohsin, H. L. Weiss, M. C. Gutierrez, G. C. Chamness, R. Schiff, M. P. DiGiovanna, C.-X. Wang, S. G. Hilsenbeck, C. K. Osborne, D. C. Allred, et al.
Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers
J. Clin. Oncol., April 10, 2005; 23(11): 2460 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
A. P Levene, G. Singh, and C. Palmieri
Therapeutic monoclonal antibodies in oncology
J R Soc Med, April 1, 2005; 98(4): 146 - 152.
[Full Text] [PDF]

Home page
 JCOHome page
J. Baselga, X. Carbonell, N.-J. Castaneda-Soto, M. Clemens, M. Green, V. Harvey, S. Morales, C. Barton, and P. Ghahramani
Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule
J. Clin. Oncol., April 1, 2005; 23(10): 2162 - 2171.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Del Mastro, F. Perrone, L. Repetto, L. Manzione, V. Zagonel, L. Fratino, D. Marenco, M. Venturini, E. Maggi, C. Bighin, et al.
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
Ann. Onc., February 1, 2005; 16(2): 253 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Bozionellou, D. Mavroudis, M. Perraki, S. Papadopoulos, S. Apostolaki, E. Stathopoulos, A. Stathopoulou, E. Lianidou, and V. Georgoulias
Trastuzumab Administration Can Effectively Target Chemotherapy-Resistant Cytokeratin-19 Messenger RNA-Positive Tumor Cells in the Peripheral Blood and Bone Marrow of Patients With Breast Cancer
Clin. Cancer Res., December 15, 2004; 10(24): 8185 - 8194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Nieto, J. J. Vredenburgh, E. J. Shpall, S. I. Bearman, P. A. McSweeney, N. Chao, D. Rizzieri, C. Gasparetto, S. Matthes, A. E. Baron, et al.
Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer
Clin. Cancer Res., November 1, 2004; 10(21): 7136 - 7143.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Perez, V. J. Suman, N. E. Davidson, P. A. Kaufman, S. Martino, S. R. Dakhil, J. N. Ingle, R. J. Rodeheffer, B. J. Gersh, and A. S. Jaffe
Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
J. Clin. Oncol., September 15, 2004; 22(18): 3700 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. B. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim
Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu
J. Immunol., July 1, 2004; 173(1): 394 - 401.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. T.H. Yeh, A. T. Tong, D. J. Lenihan, S. W. Yusuf, J. Swafford, C. Champion, J.-B. Durand, H. Gibbs, A. A. Zafarmand, and M. S. Ewer
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Circulation, June 29, 2004; 109(25): 3122 - 3131.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Karp, I. Gojo, R. Pili, C. D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, et al.
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-{beta}-D-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab
Clin. Cancer Res., June 1, 2004; 10(11): 3577 - 3585.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. D. Pegram, T. Pienkowski, D. W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, et al.
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
J Natl Cancer Inst, May 19, 2004; 96(10): 759 - 769.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Burris III, D. Yardley, S. Jones, G. Houston, C. Broome, D. Thompson, F. A. Greco, M. White, and J. Hainsworth
Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer
J. Clin. Oncol., May 1, 2004; 22(9): 1621 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. FOGLI, P. NIERI, and M. C. BRESCHI
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
FASEB J, April 1, 2004; 18(6): 664 - 675.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Tripathy, D. J. Slamon, M. Cobleigh, A. Arnold, M. Saleh, J. E. Mortimer, M. Murphy, and S. J. Stewart
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
J. Clin. Oncol., March 15, 2004; 22(6): 1063 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Lemmens, P. Fransen, S. U. Sys, D. L. Brutsaert, and G. W. De Keulenaer
Neuregulin-1 Induces a Negative Inotropic Effect in Cardiac Muscle: Role of Nitric Oxide Synthase
Circulation, January 27, 2004; 109(3): 324 - 326.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Perez and R. Rodeheffer
Clinical Cardiac Tolerability of Trastuzumab
J. Clin. Oncol., January 15, 2004; 22(2): 322 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
U. Gatzemeier, G. Groth, C. Butts, N. Van Zandwijk, F. Shepherd, A. Ardizzoni, C. Barton, P. Ghahramani, and V. Hirsh
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
Ann. Onc., January 1, 2004; 15(1): 19 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Jones
Combining trastuzumab (Herceptin(R)) with hormonal therapy in breast cancer: what can be expected and why?
Ann. Onc., December 1, 2003; 14(12): 1697 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Bianchi, J. Albanell, W. Eiermann, G. Vitali, D. Borquez, L. Vigano, R. Molina, G. Raab, A. Locatelli, B. Vanhauwere, et al.
Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5944 - 5951.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Cobleigh and D. Frame
Is Trastuzumab Every Three Weeks Ready for Prime Time?
J. Clin. Oncol., November 1, 2003; 21(21): 3900 - 3901.
[Full Text] [PDF]

Home page
 JCOHome page
B. Leyland-Jones, K. Gelmon, J.-P. Ayoub, A. Arnold, S. Verma, R. Dias, and P. Ghahramani
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel
J. Clin. Oncol., November 1, 2003; 21(21): 3965 - 3971.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Nahta and F. J. Esteva
HER-2-Targeted Therapy: Lessons Learned and Future Directions
Clin. Cancer Res., November 1, 2003; 9(14): 5078 - 5084.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
E. Rock and A. DeMichele
Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors
J. Nutr., November 1, 2003; 133(11): 3785S - 3793.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. J. Burstein, L. N. Harris, P. K. Marcom, R. Lambert-Falls, K. Havlin, B. Overmoyer, R. J. Friedlander Jr., J. Gargiulo, R. Strenger, C. L. Vogel, et al.
Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm
J. Clin. Oncol., August 1, 2003; 21(15): 2889 - 2895.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
H. Kattlove and R. J. Winn
Ongoing Care of Patients After Primary Treatment for Their Cancer
CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Geneve
Re: Demand Grows for Early Access to Promising Cancer Drugs
J Natl Cancer Inst, March 19, 2003; 95(6): 492 - 492.
[Full Text] [PDF]

Home page
 JCOHome page
H. J. Burstein, L. N. Harris, R. Gelman, S. C. Lester, R. A. Nunes, C. M. Kaelin, L. M. Parker, L. W. Ellisen, I. Kuter, M. A. Gadd, et al.
Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study
J. Clin. Oncol., January 1, 2003; 21(1): 46 - 53.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Page, D. Assouline, O. Brun, D. Coeffic, D. Fric, P. Winckel, A. D. Seidman, M. K. Pierri, and C. Hudis
Cardiac Dysfunction in Clinical Trials of Trastuzumab
J. Clin. Oncol., October 1, 2002; 20(19): 4119 - 4120.
[Full Text] [PDF]

Home page
 DTBHome page
What's so special about {blacktriangledown}trastuzumab?
DTB, September 1, 2002; 40(9): 65 - 67.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Baselga
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Oncologist, August 15, 2002; 7(90004): 2 - 8.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Speyer
Cardiac Dysfunction in the Trastuzumab Clinical Experience
J. Clin. Oncol., March 1, 2002; 20(5): 1156 - 1157.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online